upfront asct for newly diagnosed multiple myeloma: double vs. single transplant
Published 6 years ago • 132 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
1:59
the role of upfront double auto-sct in high-risk myeloma
-
1:30
exploring the role of upfront autosct in multiple myeloma
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
5:18
upfront treatment in transplant candidates
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
4:04
the future of myeloma treatment and the possibility of cure
-
4:51
the current frontline treatment strategy in multiple myeloma
-
2:30
a new era of treatment for multiple myeloma
-
4:06
treating newly-diagnosed myeloma
-
2:53
real-world data on upfront subcutaneous bortezomib-containing regimens for newly diagnosed myeloma
-
2:36
a multi-omic study to improve the diagnosis of multiple myeloma
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
2:43
targeting multiple myeloma antigens
-
3:34
maintenance therapy following salvage asct for multiple myeloma
-
2:56
early vs. deferred transplantation in al amyloidosis
-
2:44
myeloma qol through induction and maintenance
-
3:01
treatment approaches for asct-eligible myeloma patients in the frontline
-
2:25
pre-clinical activity of ucartcs1 in multiple myeloma
-
2:17
moving towards fixed-duration treatment in multiple myeloma
-
1:35
rationale for using immunotherapies in the frontline treatment of multiple myeloma
-
2:56
novel drugs for myeloma thromboprophylaxis